CRule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Bluglass Limited

ABN

20 116 825 793

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	*Class of *securities issued or to be issued	Issue of Performance Rights
		Cancellation of 1,500,000 Options with an exercise price of \$0.50, expiring on 1
		December 2018
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	16,000,000 Series A Performance Rights 2,560,112 Series B Performance Rights 1,200,000 Series C Performance Rights
3	Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the	Refer to Annexure A

dates

+convertible

conversion)

amount outstanding and due

conversion price and dates for

for

payment;

securities,

if

the

⁺ See chapter 19 for defined terms.

4	 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	No – Refer Annexure A
5	Issue price or consideration	N/A
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue of Performance Rights to Staff, Executives and Directors (as approved by Shareholders at the 2018 AGM) Cancellation of Options due to expiry
_		
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the ⁺securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	19 Nov 2018
6с	Number of *securities issued without security holder approval under rule 7.1	N/A

⁺ See chapter 19 for defined terms.

- 6d Number of *securities issued with security holder approval under rule 7.1A
- 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of securities issued under an exception in rule 7.2
- 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
- 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 Dates of entering ⁺securities into uncertificated holdings or despatch of certificates
- 8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the securities in section 2 if applicable)

Number	+Class
418,307,072	Ordinary Fully Paid

N/A

N/A

19,760,112

N/A

N/A

Refer Annexure 1

17 December 2018

+ See chapter 19 for defined terms.

		Number	+Class
9	Number and ⁺ class of all ⁺ securities not quoted on ASX (<i>including</i> the securities in section 2 if applicable)	600,000	Incentive Plan Options expiring 1 Dec 2019, \$0.01 exercise price, subject to vesting criteria
		2,000,000	Incentive Plan Options expiring 1 Dec 2020, \$0.28 exercise price, subject to vesting criteria
		16,000,000	Series A Performance Rights, expiring 17 December 2021, subject to vesting criteria
		2,560,112	Series B Performance Rights, expiring 17 December 2021, subject to vesting criteria
		1,200,000	Series C Performance Rights, expiring 17 December 2021, subject to vesting criteria

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

a e

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the ⁺ securities will be offered	
	-	

⁺ See chapter 19 for defined terms.

⁺Class of ⁺securities to which the 14 offer relates ⁺Record date to determine 15 entitlements Will holdings on different 16 registers (or subregisters) be aggregated for calculating entitlements? Policy for deciding entitlements 17 in relation to fractions 18 Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. Closing date for receipt of 19 acceptances or renunciations Names of any underwriters 20 Amount of any underwriting fee 21 or commission Names of any brokers to the 22 issue Fee or commission payable to the 23 broker to the issue Amount of any handling fee 24 payable to brokers who lodge acceptances or renunciations on behalf of +security holders If the issue is contingent on 25 +security holders' approval, the date of the meeting + See chapter 19 for defined terms. 01/08/2012 Appendix 3B Page 5

- Date entitlement and acceptance 26 form and prospectus or Product Disclosure Statement will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) Date rights trading will end (if 29 applicable) How do +security holders sell 30 their entitlements in full through a broker? How do +security holders sell 31 part of their entitlements through a broker and accept for the balance?
- 32 How do ⁺security holders dispose of their entitlements (except by sale through a broker)?
- 33 ⁺Despatch date



Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type o (<i>tick</i> o	of securities ne)
(a)		Securities described in Part 1
(b)		All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
- 36

If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories

1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

37


A copy of any trust deed for the additional *securities

Entities that have ticked box 34(b)

- 38 Number of securities for which ⁺quotation is sought
- 39 Class of ⁺securities for which quotation is sought
- 40 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment



⁺ See chapter 19 for defined terms.

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

42 Number and ⁺class of all ⁺securities quoted on ASX (*including* the securities in clause 38)

	Number	+Class
1		
ζ		
e		

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

⁺ See chapter 19 for defined terms.

We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Emmanuel Correia Company secretary Date: 17 December 2018

Print name: Emmanuel Correia

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	418,307,072	
Add the following:		
 Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 	Nil	
 Number of fully paid ordinary securities issued in that 12 month period with shareholder approval 		
Number of partly paid ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
<i>Subtract</i> the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
" A "	418,307,072	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	62,746,061	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:		
Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "I placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	62,746,061	
Note: number must be same as shown in Step 2		
Subtract "C"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	62,746,061	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	N/A	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	N/A	
Note: number must be same as shown in Step 2		
Subtract "E"	N/A	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	N/A	

⁺ See chapter 19 for defined terms.

Annexure A – Terms and Condition of Performance Rights

General Conditions

- Performance Rights to be issued will convert to Shares in the capital of the Company, which will be issued on the same terms and conditions as the Company's existing Shares;
- (b) the Performance Rights will be granted for nil cash consideration, accordingly no funds will be raised;
- (c) the following are the key terms of the Performance Rights to be granted to the Related Parties:
 - subject to any adjustment permitted under the Plan, one Performance Right will convert into one Share of the Company upon the vesting conditions being achieved;
 - (ii) the time frame to achieve the vesting conditions is three years from the date of issue;
 - (iii) if the vesting conditions are not achieved within the three period, the Performance Rights will lapse for \$nil consideration, unless the Board resolves otherwise;
 - (iv) Performance Rights will expire three years after their date of issue;

Vesting Criteria - Series A Performance Rights:

Series A Performance Rights (MD and CTO) will vest on the following basis:

Based on the Company's 30 day VWAP share price (**Share Price**) at any time after the date that is two years after the issue date of the Options as follows:

- Share Price of at least \$0.60 5,000,000 Performance Rights vest;
- Share Price of at least \$0.70 a further 5,000,000 Performance Rights vest;
- Share Price of at least \$0.80 a further 4,000,000 Performance Rights vest; and
- Share Price of at least \$0.90 a further 2,000,000 Performance Rights vest,

provided that, where, within two years of the issue date of the Performance Rights, there is a Change of Control of the Company (as defined in the Incentive Option and Performance Rights Plan) resulting from a takeover bid, and the takeover bid price is at least equal to:

- \$0.60 5,000,000 Performance Rights will vest;
- \$0.70 10,000,000 Performance Rights will vest;
- \$0.80 14,000,000 Performance Rights will vest; and
- \$0.90 16,000,000 Performance Rights will vest.

⁺ See chapter 19 for defined terms.

Vesting Criteria - Series B Performance Rights:

Series B Performance Rights (Staff and Executives) will vest on the following basis:

- 50% upon the Company entering into a meaningful commercial agreement utilizing the technology and intellectual property developed in the Lumileds collaboration; and
- 50% upon the Company demonstrating that the RPCVD hardware technology process is licensed to two or more commercial partners with recurring royalty or revenue.
- The board will retain discretion as to the satisfaction of the vesting conditions based on the materiality and importance to the Company of achieving the predefined performance criteria.

Vesting Criteria - Series C Performance Rights:

Series C Performance Rights (Directors) will vest on the following basis:

- 35% upon the Company entering into a meaningful commercial agreement utilizing the technology and intellectual property developed in the Lumileds collaboration;
- 35% upon the Company demonstrating that the RPCVD hardware technology process is licensed to two or more commercial partners with recurring royalty or revenue; and
- 30% allocated as 10% per year for each year of service for a period of three years from the issue date of the Performance Rights.
- The board will retain discretion as to the satisfaction of the vesting conditions based on the materiality and importance to the Company of achieving the pre-defined performance criteria.

⁺ See chapter 19 for defined terms.